Compounds > proxodolol
Page last updated: 2024-11-07

proxodolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

proxodolol: structure given in first source (3-methoxy- instead of 3-methyl-; text of article gives name as 3-methyl-; see also article on page 27 of the same source) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133047
MeSH IDM0234576

Synonyms (11)

Synonym
proxodolol
1-(tert-butylamino)-3-[2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy]propan-2-ol
unii-95n3wb936t
(+/-)-1-(2-((3-methoxy-1,2,4-oxadiazol-5-yl)methoxy)phenoxy)-3-((tert-butylamino))propan-2-ol
zoleprodolol [inn]
158599-53-2
95n3wb936t ,
zoleprodolol
(+/-)-1-(2-((3-methoxy-1,2,4-oxadiazol-5-yl)methoxy)phenoxy)-3-(tert-butylamino)propan-2-ol
Q27271805
AKOS040754576

Research Excerpts

Toxicity

Proxodolol is effective and safe in hypertension. In a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.

ExcerptReferenceRelevance
"The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011)		0.37
"Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011)		0.37

Dosage Studied

ExcerptRelevanceReference
"To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH)."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (44.44%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (55.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carvedilol
[no description available]		7.0610carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		4.3441
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalopathy, Hypertensive
[description not available]		02.0510
Malignant Hypertension
[description not available]		02.0510
Acute Disease
Disease having a short and relatively severe course.		02.0510
Hypertension, Malignant
A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.		02.0510
Acute Coronary Syndrome
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.		02.0510
Cardiac Failure
[description not available]		02.0610
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		07.0610
Blood Pressure, High
[description not available]		03.8121
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		03.8121